|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||140.92 - 141.78|
|52 Week Range||111.09 - 141.78|
|PE Ratio (TTM)||69.72|
|Expense Ratio (net)||0.06%|
An activist group at Vanguard is asking shareholders to vote in favor of a proposal that would not allow the mutual fund giant to invest in companies that contribute to genocide or crimes against humanity. Yahoo Finance’s Alexis Christoforous, Ethan Wolff-Mann and Dan Roberts talk about why Vanguard is recommending its clients to vote against the proposal.
Why is Vanguard voting against a shareholder measure on its proxy ballot that moves to stop investing in companies that "substantially contribute" to genocide?
This has been another year of brisk new product launches from the exchange-traded funds industry as hundreds of new funds have come to market. As is often the case, some new ETFs take awhile to attract ...
According to a Deloitte report, the biosimilars market is expected to grow to a market value of more than $445.0 billion by the end of 2019.
This year, the growth factor resumed its outperformance of the value factor, benefiting a host of exchange traded funds along the way. Investors can easily access growth stocks via ETFs, whether be by ...
ETF adoption has rapidly accelerated in recent years, with many investors steering to cheap ETFs to potentially bolster long-term investment returns. There are 2,040 U.S.-listed ETFs on the market with ...
Boston Scientific (BSX) expects to register 2017 revenues of $8.9 billion–$9.0 billion compared to its previous guidance of $8.8 billion–$8.9 billion.
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter ...
On June 19, 2017, Medtronic (MDT) experienced a global technology glitch, which led to IT disruption throughout the company.
Becton Dickinson (BDX) is the leading player in the US dispensing business. Its Pyxis system sales contribute significantly to the company’s total revenues.
The proton therapy market is a highly lucrative opportunity area for Varian Medical Systems (VAR). Proton therapy uses protons for treating cancer instead of X-rays. According to a Medgadget report,…
In 2Q17, Celgene’s (CELG) Otezla generated revenues of around $358 million, which reflected ~49% growth on a year-over-year basis.
For fiscal 1Q18, Kors's EPS came in at $0.90, or $0.28 higher than the estimate. Its revenue fell 3.6% YoY to $952 million but still beat the consensus estimate.
Michael Kors Holdings Limited (KORS) is slated to report its 1Q18) earnings results on Tuesday, August 8. Here's what you need to know.